FDA
-
-
-
-
-
-
-
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
-
-
-
-
-
-
-
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
-
-
-
-
-
-
-
Bayer's asundexian reduces stroke risk by 26% in phase III trial
-
-
-
-
-
-
-
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
-
-
-
-
-
-
-
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
-
-
-
-
-
-
-
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
-
-
-
-
-
-
-
Eiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of Directors
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

